The Role of JAK2 Mutation in Thrombotic Complications of Chronic Myeloproliferative Neoplasms

The Role of JAK2 Mutation in Thrombotic Complications of Chronic Myeloproliferative Neoplasms

July 31, 2014 at 9:41 AM 0 comments

*Viola M. Popov,1 Minodora Onisai,2 Mihaela Găman,2 Ana Maria Vladareanu2 1. Hematology Department, Colentina Clinical Hospital, Bucharest, Romania 2. ‘Carol Davila’ University of Medicine and Pharmacy, Department of Hematology, Emergency University Hospital, Bucharest, Romania *Correspondence to violamariap@gmail.com Disclosure: No potential conflict of interest. Received: 01.04.14 Accepted: 01.06.14 Citation: EMJ Hema.Read More

Calreticulin in Myeloproliferative Neoplasms: The Other Side of the Alice Mirror

Calreticulin in Myeloproliferative Neoplasms: The Other Side of the Alice Mirror

July 31, 2014 at 9:35 AM 0 comments

Lilian Varricchio, *Anna Rita Migliaccio Tisch Cancer Institute, Mount Sinai School of Medicine, New York, USA *Correspondence to annarita.migliaccio@mssm.edu Disclosure: No potential conflict of interest. Received: 31.03.14 Accepted: 20.05.14 Citation: EMJ Hema. 2014;1:114-122. Abstract Calreticulin (CALR), a Ca2+ binding protein mostly localised in the endoplasmic reticulum, regulates Ca2+ homeostasis, chaperones,Read More

Iron Supplementation for Perioperative Anaemia in Patient Blood Management

Iron Supplementation for Perioperative Anaemia in Patient Blood Management

July 31, 2014 at 9:30 AM 0 comments

*Manuel Muñoz,1 Susana Gómez-Ramírez,2 Arturo Campos3 1. Perioperative Transfusion Medicine, School of Medicine, University of Málaga, Málaga, Spain 2. Department of Internal Medicine, University Hospital Virgen de la Victoria, Málaga, Spain 3. Department of Hematology and Clinical Laboratory, University Hospital Virgen de la Victoria, Málaga, Spain *Correspondence to mmunoz@uma.es Disclosure:Read More

Looking Back To Our Roots: 80 Years of Wintrobe’s Indices

Looking Back To Our Roots: 80 Years of Wintrobe’s Indices

July 31, 2014 at 9:26 AM 0 comments

*Eloísa Urrechaga,1 Silvia Izquierdo,2 Jesús F. Escanero3 1. Laboratory, Hospital Galdaka-Usansolo, Hematology Laboratory, Galdakao, Spain 2. Clinical Genetics, Service of Clinical Biochemistry, Miguel Servet University Hospital, Zaragoza, Spain 3. University of Zaragoza, Faculty of Medicine, Department of Pharmacology and Physiology, Zaragoza, Spain *Correspondence to eloisa.urrechagaigartua@osakidetza.net Disclosure: No potential conflict ofRead More

Preventing Infections in Higher-Risk Myelodysplastic Syndrome Patients Treated with Hypomethylation Agents

Preventing Infections in Higher-Risk Myelodysplastic Syndrome Patients Treated with Hypomethylation Agents

December 29, 2013 at 5:21 PM 0 comments

Yishai Ofran Department of Hematology and Bone Marrow Transplantation; Rambam Health Care Campus. Bruce Rappaport Faculty of Medicine, Technion, Haifa, Israel Citation: EMJ Hema. 2013;1:58-63. Abstract Hypomethylation agents became the standard of care for patients with high-risk myelodysplastic syndrome (MDS). While long-term benefits of azacitidine (AZA) and decitabine (DEC) wereRead More

RNA Interference (RNAi): An Effective Way to Develop Rational Combination Therapies with Hypomethylating Agents in Acute Leukaemias and Myelodysplastic Syndrome

RNA Interference (RNAi): An Effective Way to Develop Rational Combination Therapies with Hypomethylating Agents in Acute Leukaemias and Myelodysplastic Syndrome

December 29, 2013 at 5:18 PM 0 comments

Raoul Tibes Senior Associate Consultant, Director Acute and Chronic Leukemia Program, Division of Hematology & Medical Oncology, Assistant Professor, Mayo College of Medicine, Mayo Clinic/Mayo Clinic Cancer Center, Arizona, USA Disclosure: No potential conflict of interest. Citation: EMJ Hema. 2013;1:53-57. Abstract Therapeutic progress in aggressive myeloid malignancies such as acuteRead More

Treatment of HIV-Associated Burkitt Lymphoma

Treatment of HIV-Associated Burkitt Lymphoma

December 29, 2013 at 2:27 AM 0 comments

Giovanni Donadoni,1,2 Marta Bruno-Ventre,1,3 Andrés J. M. Ferreri1,2 1. Unit of Lymphoid Malignancies 2. Division of Onco-Hematological Medicine 3. Unit of Hematology and Bone Marrow Transplantation Department of Onco-Hematology, San Raffaele Scientific Institute, Milan, Italy Disclosure: No potential conflict of interest. Citation: EMJ Hema. 2013;1:38-52. Abstract Burkitt lymphoma (BL) isRead More

Pain Management in Patients with Sickle Cell Disease – A Review

Pain Management in Patients with Sickle Cell Disease – A Review

December 29, 2013 at 2:24 AM 0 comments

Sophia Delicou, Konstantinos Maragkos Thalassemia Unit, Ippokrateion General Hospital, Athens, Greece Disclosure: No potential conflict of interest. Citation: EMJ Hema. 2013;1:30-36. Abstract Pain is defined, by the International Association for the Study of Pain (IASP), as an ‘unpleasant sensitive and emotional experience, associated with or described in terms of tissueRead More

The Chemokine CCL17/TARC as a Biomarker in Hodgkin Lymphoma

The Chemokine CCL17/TARC as a Biomarker in Hodgkin Lymphoma

December 29, 2013 at 2:22 AM 0 comments

Maike Sauer,1 Sabine Ponader,1,2 Andreas Engert,2 and Elke Pogge von Strandmann1 1. Innate Immunity Group, Department of Internal Medicine I, University Hospital Cologne, Cologne, Germany 2. German Hodgkin Study Group, Department of Internal Medicine I, University Hospital Cologne, Cologne, Germany Disclosure: No potential conflict of interest. Citation: EMJ Hema. 2013;1:25-29. AbstractRead More

Delayed Erythroid and Platelet Response to Eculizumab in Paroxysmal Nocturnal Haemoglobinuria – A Case Report and Literature Review

Delayed Erythroid and Platelet Response to Eculizumab in Paroxysmal Nocturnal Haemoglobinuria – A Case Report and Literature Review

December 29, 2013 at 2:18 AM 0 comments

Andres L. Brodsky, Laura B. Colin Hospital de Clinicas ‘Jose de San Martin’, Hematology Division, Department of Medicine, University of Buenos Aires, Argentina Disclosure: No potential conflict of interest. Citation: EMJ Hema. 2013;1:20-24. Abstract Paroxysmal nocturnal haemoglobinuria (PNH) is an acquired clonal disorder of haemopoiesis characterised by haemolytic anaemia, thrombophiliaRead More